Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
FLKR vs XBI: how they differ
FLKR and XBI hold 0% of their weight in the same names, and FLKR returned more over the year.
Franklin FTSE South Korea ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, FLKR and XBI hold 0% of their money in the same securities at the same weight.
| Only in FLKR | Only in XBI |
|---|---|
| SK HYNIX INC 23.85% | Apogee Therapeutics Inc 1.49% |
| SAMSUNG ELECTRONICS CO LTD 15.68% | Moderna Inc 1.41% |
| UNITED STATES OF AMERICA - BUREAU OF THE 13.10% | Twist Bioscience Corp 1.41% |
| SK SQUARE CO LTD 3.75% | Oruka Therapeutics Inc 1.38% |
| SAMSUNG ELECTRO MECHANICS 3.64% | Kymera Therapeutics Inc 1.36% |
| HYUNDAI MOTOR COMPANY 2.14% | Viking Therapeutics Inc 1.31% |
| KB FINANCIAL GROUP INC 1.75% | Praxis Precision Medicines Inc 1.29% |
| SAMSUNG ELECTRONICS CO LTD 1.73% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| FLKR Franklin FTSE South Korea ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Franklin | State Street |
| What it is | FTSE South Korea | SPDR S&P Biotech |
| Total return, 1 year | +146.0% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | +128.5 pts | +46.5 pts |
| Expense ratio | 0.09% | 0.35% |
| Already in the S&P 500 | 0.0% | 8.5% |
| Holdings | 157 | 150 |
FLKR in plain words
FLKR is an index equity fund tracking the FTSE South Korea. Over the year to Sep 11, 2026 it returned +146.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.09% a year. By its holdings filed for Jun 30, 2026, 0% of the fund by weight is stocks the S&P 500 also holds, across 157 positions, with the top ten at 68.2%. It sat 13.6% below its high of Jun 22, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, FLKR or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, FLKR returned +146.0% and XBI returned +64.0%, so FLKR returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, FLKR or XBI?
- FLKR charges 0.09% a year and XBI charges 0.35%, so FLKR is cheaper. Fees come from each fund's prospectus.
- How much do FLKR and XBI overlap with the S&P 500?
- By their latest filed holdings, 0% of FLKR and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, FLKR against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/FLKR-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources